International Clinical Trial: A Prospective, Single-Arm Clinical Study of Neoadjuvant Low-Dose Radiotherapy Combined With Vibepolimab and Pucilizumab in Locally Advanced Resectable EGFR-Positive Esophageal Squamous Cell Carcinoma (ESCC-LDR-03)

Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124196) titled 'A Prospective, Single-Arm Clinical Study of Neoadjuvant Low-Dose Radiotherapy Combined With Vibepolimab and Pucilizumab in Locally Advanced Resectable EGFR-Positive Esophageal Squamous Cell Carcinoma (ESCC-LDR-03)' on May 8.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Daping Hospital, Army Medical University

Condition: Esophageal Squamous Cell Carcinoma

Recruitment Status: Recruiting

Phase: 2

Date of First Enrollment: 2026-05-08

Target Sample Size: intervention group:30;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=32...